Cerevance

Biotech · Private

Brain cell type-specific transcriptomics platform for identifying CNS drug targets

cerevance.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
8
0 granted · 8 pending
Sector median: 2

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1355Allegro 3D, Inc.——
1356FoodSource Lure Corporation——
1357TANDA BIOTECH CORPORATION——
1358Cerevance——
1359FIBROSIX INC.——
1360PARAMITA THERAPEUTICS, INC.——
1361Abceutics——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 0 granted of 8
  • Nicotinamide Derivatives For Use In Treating Disorders Associated With KCNK13 Activityapplication
  • Nitrogen Comprising Heterocyclic Derivatives For The Treatment Of Disorders Associated With GPR55 Receptorapplication
  • N-(4-aminocyclohexyl)pyrimidine-4-carboxamide derivatives as CD38 inhibitorsapplication
  • Novel Compoundsapplication
  • Heterobicyclic amides as inhibitors of CD38application
  • 3-CARBONYL IMIDAZO[1,5-A]PYRIDINE Derivatives For Use As CD38 Inhibitors For The Treatment Of Cns Disordersapplication
  • 1,3-THIAZOLE And 1,2,4-THIADIAZOLE Derivatives For Use As CD38 Inhibitors For The Treatment Of Cns Disordersapplication
  • Diaryl Diazole And Diaryl Triazole Derivatives For Use In Treating A Disease Associated With KCNK13 Activityapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.